📇 Rhumatologue · GOUSSAINVILLE · (95) · Salarié

M FREDERIC TAZIERE

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
82.6 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 GOUSSAINVILLE (95)SalariéRPPS 10001318285

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(3)

CDS MUNICIPAL PIERRE ROUQUES
2 R DE LATTRE DE TASSIGNY, 95190 GOUSSAINVILLE
☎ 0139887644Activité non soignante
CDS MUNICIPAL JULIETTE TENINE
8 R JEAN BAPTISTE LEBON, 92000 NANTERRE
☎ 0189354200Activité non soignante

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation

Kidney international · 2023

📚 29 citations🎯 RCR 5.28Top 7% NIH🔓 Open Access📄 PDF gratuit ↗

Evaluating the impact of COVID-19 on cancer declarations in Quebec, Canada

Cancer medicine · 2023

📚 16 citations🎯 RCR 2.21Top 24% NIH🔓 Open Access

Lire l'abstract Crossref ↓

AbstractBackgroundCOVID‐19 affected healthcare worldwide, limited access to healthcare, and delayed cancer screening and diagnosis. In this study, the effect of the first year of COVID‐19 was determined on cancer diagnoses in the province of Quebec, Canada.MethodsData were collected from the 13 Quebec Cancer Registry health institutions. Newly diagnosed cancer declarations in the first year of the COVID‐19 (April 2020–March 2021) were compared with the reference periods (averages of 3 previous years). The main focus was on four leading cancers: lung, prostate, colorectal, and breast cancers. Generalized regression models with a poisson approximation and interrupted time series (ITS) analysis were used. Underestimated cases were presented in terms of relative risk (RR) and 95% confidence intervals (CI). The changes in the stage‐specific counts were also assessed in each of the four cancers. Results were illustrated separately for the first 4 months of the pandemic (first wave).FindingsThis study estimated an overall under‐reporting of 15.3% (29,019 vs. 24,584) of declarations. This under‐reporting was evident across all age groups above 35 years (p < 0.0001), four primary cancers (p < 0.0001), all stages of cancers (p < 0.0001), and both sexes (p < 0.0001). Based on the relative risks, stage‐specific lung cancer counts were underestimated by 5%–34% in the first wave (0%–11% in the first year), prostate cancer by 16%–46% in the first wave (0%–25% in the first year), colorectal cancer 15%–45% in the first wave (0%–24% in the first year), and breast cancer 3%–45% in the first wave and (0%–28% in the first year). However, no stage‐IV cancers were statically under‐reported compared to the pre‐pandemic era and not even in the first wave.InterpretationCancer diagnosis was underestimated due to the COVID‐19 pandemic in the first year; this effect was more evident in the first phase of the pandemic in Quebec. Further research is required to determine the accurate burden of the disease in the long term.

Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia

Stem cells translational medicine · 2022

📚 14 citations🎯 RCR 1.37🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract As in younger patients, allogeneic stem cell transplantation (alloHSCT) offers the best chance for durable remission in older patients (≥60 years) with acute myeloid leukemia (AML). However, defining the best treatment strategy (and in particular, whether or not to proceed to alloHSCT) for elderly patients with AML remains a difficult decision for the hematologist, since potential toxicity of conditioning regimens, risks of graft-versus-host disease, impaired immune reconstitution and the need for prolonged immunosuppression may be of major concern in these vulnerable patients with complex needs. Hopefully, significant progress has been made over the past decade in alloHSCT for elderly patients and current evidence suggests that chronological age per se (between 60 and 75) is not a reliable predictor of outcome after alloHSCT. Here, we review the current state of alloHSCT in elderly patients with AML and also discuss the different approaches currently being investigated to improve both accessibility to as well as success of alloHSCT in these patients.

Cookies & analyse de trafic

M FREDERIC TAZIERE

Pourquoi vous devez consulter ce praticien

Lieux de consultation(3)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (24) — classées par pathologie

Transversal10

Pédiatrie3

Revue générale3

Case report / série2

Épidémiologie & registres2

Gériatrie2

Économie santé1

Essai clinique1

Génétique1

Lupus1

Pharmacovigilance1

Partager cette fiche